July 28, 2016
The FDA approved Xiidra for the treatment of signs and symptoms of dry eye disease in adult patients on July 11.
Manufactured by Shire, Xiidra (lifitegrast ophthalmic solution 5%) is the first prescription eye drop medication in a new class of drugs, a lymphocyte function-associated antigen 1 antagonist, to be approved by the FDA for dry eye disease, according to an FDA press release. The drug’s safety and efficacy were assessed in more than 2,500 patients in four separate, randomized controlled studies. The results of the studies found that patients treated with Xiidra demonstrated improvement in their signs and symptoms of dry eye compared with patients treated with placebo.